Clinical Trials
11 trialsNCT03357952 2025-02-04
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2/3 Completed
NCT00177047 2021-11-09
Autologous Transplant for Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Phase 2/3 Completed
NCT00657488 2019-10-18
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
Phase 2/3 Completed
NCT00038090 2018-10-31
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed
NCT00861250 2016-06-17
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Tampere University Hospital
Phase 2/3 Completed
NCT00514371 2015-12-07
TIME-2
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00205751 2013-11-25
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Austrian Forum Against Cancer
Phase 2/3 Completed
NCT00090493 2013-06-24
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
University of Arkansas
Phase 2/3 Completed
NCT01085058 2010-03-11
CU01
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2/3 Completed
NCT00300664 2006-10-13
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
Royal Marsden NHS Foundation Trust
Phase 2/3 Completed